Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2016, vol. 25, nr 3, May-June, p. 569–573

doi: 10.17219/acem/41923

Publication type: review article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Clinical Aspects of the Use of Botulinum Toxin Type A in the Treatment of Dysfunction of the Masticatory System

Zdzisław A. Bogucki1,A,D,E,F, Mariola Kownacka2,B,C,D

1 Division of Dental Materials, Faculty of Dentistry, Wroclaw Medical University, Poland

2 Division of Dental Prosthetics, Faculty of Dentistry, Wroclaw Medical University, Poland


The purpose of this work is to present a new, still experimental method of treating temporomandibular disorders (TMD) by injecting botulinum toxin Type A (TBX-A), using its effects not as a toxin but as a medication. The mechanism of TBX-A, indications and contraindications for its use, as well as possible side effects, are discussed. Temporomandibular disorders are of concern to approximately 70–80% of the population. The effect of botulinum toxin depends on blocking the release of acetylcholine from a presynaptic neuromuscular synapse and, in the autonomous system, blocking its release from post-ganglionic cholinergic neurons. In cases of long-term TMJ disorders, muscle activity increases and spastic contractions may even appear. TBX-A offers an opportunity for a normal social and family life for many patients suffering from masticatory system disorders (MSD), who have been isolated from the environment by pain. The study is based on a review of the literature and the authors’ own experiences during several attempts to treat patients by this method. TBX-A is a safe medicine when the injection is performed by a well-trained physician.

Key words

botulinum toxin type A, dysfunction of the masticatory system, stomatognathic system

References (13)

  1. Esmara AS, Faramawey MI, Hassan MA, Hakam MM: Botulinum toxin injection for management of teporomandibular joint clicking. Int J Oral Maxillofac Surg 2013, 42, 759–764.
  2. Freund B, Schwartz M, Symington JM: Botulinum toxin: New treatment for temporomandibular disorders. Br J Oral Maxillofac Surg 2000, 38, 466–471.
  3. Pihut M, Wiśniewska G, Majewski S: Domięśniowe iniekcje toksyny botulinowej typu A w leczeniu bólowej postaci dysfunkcji narządu żucia – wyniki badaż pilotażowych. Prot Stomatol 2009, 5, 312–320.
  4. Ernberg M, Hedenberg-Magnusson B, Lista T, Svensson P: Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: A randomized, controlled, double-blind multicenter study. Pain 2011, 152, 1988–1996.
  5. Kai-Yuan Fu: Long-term efficacy of botulinum toxin type A for the treatment of habitual dislocation of the temporomandibular joint. Br J Oral Maxillofac Surg 2010, 48, 281–284.
  6. Pihut M, Wiśniewska G, Majewski P, Gronkiewicz K, Majewski S: Measurement of occlusal forces in the therapy of functional disorders with the use of botulinum toxin type A. J Physiol Pharmacol 2009, 60, Suppl 8, 113–116.
  7. Bakke M: Treatment of severe temporomandibular joint clicking with botulinum toxin in the lateran pterygoid muscle. In two cases of anterior disc displacement. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005, 100, 693–700.
  8. Von Lindern JJ, Niederhagen B, Bergé S, Appel T: Type A Botulinum Toxin in the Treatment of Chronic Facial Pain Associated With Masticatory Hyperactivity. J Oral Maxillofac Surg 2003, 61, 774–778.
  9. Stubblefield MD, Levine A, Custodio CM, Fitzpatrick T: The role of botulinum toxin type A in the radiation fibrosis syndrome:a preliminary report. Arch Phys Med Rehabil 2008, 89, 417–421.
  10. Alvaro-Gonzales LC, Fernandez-Garcia JM, Aranzabal-Alustiza I, Castillo-Calvo B, Iriondo-Etxenagusia I, Rodriquez-Antiquedad A: Botulinum toxin A in chronic refractory migraine: Premarketing experience. Rev Neurol 2012, 55, 385–391.
  11. Stubblefield MD, Manfield L, Riedel ER: A preliminary report on the efficacy of a dynamic jaw opening device (dynasplint trismus system) as part of the multimodal treatment of trismus in patients with head and neck cancer. Arch Phys Med Rehabil 2010, 91, 1278–1282.
  12. Da Costa Ribeiro R, dos Santos Jr. BJ, Provenazano N, de Freitas PHL: Dautrey’s procedure: An alternative for the treatment of recurrent mandibular dislocation in patients with pneumatization of the articular eminence. Maxillofacial Surg 2014, 43, 465–469.
  13. Sidebottom AJ: Current thinking in temporomandibular joint management. Br J Oral Maxillofac Surg 2009, 47, 91–94.